Spinal muscular atrophy (SMA) is a genetic disease in which progressive loss of motor neurons causes muscle weakness and atrophy. Severity ranges from severe infantile onset (SMA Type I, often fatal) to milder forms with later onset (Types II, III, IV). Modern gene therapies and antisense treatments have transformed prognosis dramatically.
Antisense oligonucleotide therapy (nusinersen/Spinraza) modifies pre-mRNA splicing to increase functional SMN protein production; administered intrathecally every 4 months after induction. Gene replacement therapy (onasemnogene abeparvovec/Zolgensma) delivers a functional SMN gene via AAV vector; one-time IV infusion, reserved for infants <2 years old. Risdiplam (Evrysdi) is an oral small molecule promoting SMN exon inclusion; daily dosing. These treatments slow or arrest progression and improve survival dramatically. Supportive care includes physiotherapy, respiratory support (non-invasive ventilation or tracheostomy in severe cases), nutritional support, and orthotic devices.
No evidence-based alternatives exist for SMA's genetic cause. Supportive therapies—physiotherapy, adaptive equipment—complement gene and antisense therapy but are not standalone treatments.
Mesenchymal stem cell therapy has been explored in preclinical SMA models and is offered commercially in some clinics, but clinical evidence is sparse. Regenerative approaches do not address the underlying genetic deficiency and are not standard. Gene therapy and antisense treatments are the current disease-modifying gold standard.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Nusinersen (Spinraza) | Standard | Strong | €400,000–600,000/year | Medium | Intrathecal injection; disease stabilisation; ongoing infusions |
| Onasemnogene Abeparvovec (Zolgensma) | Standard | Strong | €1,500,000 (one-time) | Medium | Single IV infusion; progressive improvement over months; durable effect |
| Risdiplam (Evrysdi) | Standard | Strong | €300,000–450,000/year | Low | Oral daily; disease arrest; long-term data accumulating |
| Physiotherapy & Rehabilitation | Standard | Strong | €60–100/session | Low | Ongoing; maintains function; prevents contractures |
| Non-invasive Ventilation Support | Standard | Strong | €500–2,000/month (rental) | Low | Night-time use; improves sleep quality and survival |
| Nutritional Support & Feeding Strategies | Standard | Strong | €100–300/month | Low | Ongoing; prevents malnutrition |
| Mesenchymal Stem Cell Infusion | Regenerative | Investigational | €15,000–35,000 | Medium | 1–2 weeks; unproven benefit; should not delay approved therapies |
| Spinal Orthoses & Mobility Aids | Standard | Moderate | €1,000–5,000 | Low | Immediate; improves posture and mobility |
Nusinersen, risdiplam, and gene therapy do not cure SMA but halt or reverse progression. Patients maintain or gain strength; long-term outcomes are dramatically better than historically. Lifelong monitoring and continued therapy are needed.
Zolgensma is approved for infants <2 years; earlier treatment yields better outcomes. Nusinersen and risdiplam can be used across ages. Treatment should begin as soon as diagnosis is confirmed; delay risks irreversible muscle loss.
Mesenchymal stem cells are being investigated but do not address SMA's genetic cause. Antisense and gene therapies directly target the SMN deficiency and are far more effective; stem cell therapy should not delay approved treatments.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită